Royal Bank Of Canada Issues Positive Forecast for Insulet (NASDAQ:PODD) Stock Price

Insulet (NASDAQ:PODD) had its target price raised by Royal Bank Of Canada from $365.00 to $370.00 in a report published on Friday morning,Benzinga reports. The brokerage currently has an outperform rating on the medical instruments supplier’s stock.

Several other equities research analysts have also issued reports on the company. Wolfe Research lifted their price objective on Insulet from $350.00 to $375.00 and gave the company an “outperform” rating in a research note on Friday. Weiss Ratings restated a “hold (c)” rating on shares of Insulet in a research note on Wednesday, October 8th. Oppenheimer lifted their price target on Insulet from $324.00 to $365.00 and gave the company an “outperform” rating in a research report on Monday, September 8th. Barclays boosted their price objective on Insulet from $300.00 to $301.00 and gave the stock an “equal weight” rating in a report on Wednesday. Finally, Rothschild & Co Redburn raised their target price on shares of Insulet from $350.00 to $370.00 and gave the company a “buy” rating in a research note on Friday, October 3rd. One investment analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $370.76.

Insulet Price Performance

NASDAQ:PODD traded down $3.58 during mid-day trading on Friday, hitting $319.82. 677,166 shares of the stock traded hands, compared to its average volume of 721,278. The business’s 50-day moving average price is $325.06 and its 200 day moving average price is $309.40. The company has a quick ratio of 1.81, a current ratio of 2.26 and a debt-to-equity ratio of 0.64. The company has a market cap of $22.51 billion, a PE ratio of 97.21, a price-to-earnings-growth ratio of 2.64 and a beta of 1.39. Insulet has a 12-month low of $230.05 and a 12-month high of $353.50.

Insulet (NASDAQ:PODD) last announced its quarterly earnings results on Thursday, November 6th. The medical instruments supplier reported $1.24 EPS for the quarter, beating the consensus estimate of $1.13 by $0.11. The firm had revenue of $521.70 million during the quarter, compared to the consensus estimate of $678.70 million. Insulet had a net margin of 10.01% and a return on equity of 23.78%. The business’s quarterly revenue was up 29.9% compared to the same quarter last year. During the same period last year, the firm earned $1.08 EPS. Insulet has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. On average, analysts expect that Insulet will post 3.92 EPS for the current fiscal year.

Insider Activity at Insulet

In related news, SVP Prem Singh sold 687 shares of the stock in a transaction on Monday, September 8th. The shares were sold at an average price of $347.49, for a total transaction of $238,725.63. Following the transaction, the senior vice president owned 3,456 shares of the company’s stock, valued at approximately $1,200,925.44. This trade represents a 16.58% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Laetitia Cousin sold 797 shares of Insulet stock in a transaction on Monday, September 8th. The stock was sold at an average price of $348.81, for a total transaction of $278,001.57. Following the completion of the transaction, the senior vice president owned 3,890 shares in the company, valued at approximately $1,356,870.90. The trade was a 17.00% decrease in their position. The SEC filing for this sale provides additional information. Company insiders own 0.39% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the stock. Crossmark Global Holdings Inc. increased its position in shares of Insulet by 3.4% in the first quarter. Crossmark Global Holdings Inc. now owns 3,036 shares of the medical instruments supplier’s stock valued at $797,000 after acquiring an additional 100 shares during the period. Banque Pictet & Cie SA raised its position in Insulet by 129.9% during the 1st quarter. Banque Pictet & Cie SA now owns 2,529 shares of the medical instruments supplier’s stock valued at $664,000 after purchasing an additional 1,429 shares during the last quarter. Nisa Investment Advisors LLC lifted its holdings in Insulet by 69.7% in the 1st quarter. Nisa Investment Advisors LLC now owns 7,445 shares of the medical instruments supplier’s stock worth $1,955,000 after buying an additional 3,057 shares during the period. Cerity Partners LLC lifted its holdings in Insulet by 28.7% in the 1st quarter. Cerity Partners LLC now owns 10,232 shares of the medical instruments supplier’s stock worth $2,687,000 after buying an additional 2,284 shares during the period. Finally, Genus Capital Management Inc. grew its position in shares of Insulet by 202.4% in the 1st quarter. Genus Capital Management Inc. now owns 17,008 shares of the medical instruments supplier’s stock worth $4,466,000 after buying an additional 33,611 shares during the last quarter.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.